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Abstract
Background: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with
non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required;
however, a method to monitor the effect and the safety of dabigatran is not currently available. The Global
Thrombosis Test (GTT) is a novel method to assess both clot formation and lysis activities under physiological
conditions.
Objective: The aim of this study was to evaluate whether treatment with dabigatran might affect shear-induced
thrombi (occlusion time [OT], sec) by the GTT, and to investigate the possibility that the GTT could be useful as a
monitoring system for dabigatran.
Patients/Methods: The study population consisted of 50 volunteers and 43 NVAF patients on WF therapy, who
were subsequently switched to dabigatran. Using the GTT, the thrombotic status was assessed one day before and
1 month after switching anticoagulation from WF to dabigatran.
Results: The OT was 524.9 ± 17.0 sec in volunteers whereas that of NVAF patients on WF therapy was 581.7 ± 26.3 sec.
The switch from WF to dabigatran significantly prolonged OT (784.5 ± 19.3 sec). One patient on WF therapy and 12
patients on dabigatran therapy were shown to have OT > 900 sec.
Conclusion: The GTT could be used to assess the risk of dabigatran-related bleeding complications.
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Introduction
Anticoagulation is recommended for the prevention of
thrombotic events in the majority of patients with atrial
fibrillation (AF). Warfarin is a well-established anti-
coagulant; however, there are some limitations including
large inter-individual variability in dose–response and its
narrow therapeutic window. Furthermore, treatment
with warfarin requires routine analytical work-ups and
visits to monitor prothrombin time-international nor-
malized ratio (PT-INR); therefore this therapy may ad-
versely affect health-related quality of life. Novel oral
anticoagulants (NOAC), including dabigatran are alter-
natives to warfarin for preventing thromboembolic
events in patients with non-valvular AF (NVAF). Recent
clinical trials have demonstrated the non-inferiority of
NOACs to warfarin in this setting [1, 2]. The major ad-
vantage of NOAC over warfarin is that routine labora-
tory monitoring is claimed to be dispensable. However,
there are no clinical tools available to indicate the bio-
activity of NOAC and the risk of major bleeding, similar
to the PT-INR, as is the case with warfarin.
The Global Thrombosis Test (GTT) is a novel compre-
hensive test of platelet reactivity, coagulation (thrombin
generation), and spontaneous (endogenous) thrombolytic
activity. This in vitro assay system evaluates both high-
shear-induced thrombotic reactions and subsequent
thrombolysis under physiological conditions by using
non-anticoagulated blood samples. The GTT evaluates
the time required to form an occlusive thrombus (occlu-
sion time [OT]), and the time to lyse this thrombus (lysis
time [LT]) are evaluated by the GTT [3]. Recently, we
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reported the validity of GTT as a monitoring system [4].
The aim of this study was to evaluate whether treatment
with dabigatran might affect the OT or LT assessed by the
GTT, and to investigate the possibility that the GTT could
be useful as a monitoring system to evaluate the effect of
dabigatran.
Methods
Study Protocol
The study population consisted of 50 Japanese vol-
unteers not taking antithrombotic treatment (Male/
Female = 27/23, 69.2 ± 1.3 y.o.) as well as 43 Japanese
NVAF patients receiving warfarin therapy (Male/Female =
27/16, 76.5 ± 1.4 y.o.). The patients regularly visited at the
outpatient clinic of Kobe Rosai Hospital. The value of PT-
INR of NVAF patients receiving warfarin was 1.83 ± 0.1.
The study protocol is shown in Fig 1 and the clinical
profile of subjects is shown in Table 1. The average
CHA2DS2-VASc score of NVAF patients was 4.14 ± 0.21,
and 60.5 % of patients had a CHA2DS2-VASc score ≥ 4.
The average HAS-BLED score was 1.86 ± 0.16, and 32.6 %
of patients had a CHA2DS2-VASc score ≥ 3. The throm-
botic status of all patients was assessed one day before and
1 month after switching anticoagulation from warfarin to
dabigatran (Prazaxa, Boehringer-Ingelheim, Germany) at a
dose of 110 mg b.i.d or 150 mg b.i.d, with the GTT, PT-
INR and APTT.
The present study was approved by the hospital ethics
committee, and written informed consent was obtained
from all patients.
Global Thrombosis Test
The GTT is a novel, point-of-care assay that employs na-
tive (non-anticoagulated) blood. The instrument assesses
the time taken to create a shear-induced thrombus under
physiological conditions and in the second phase of the
test, measures the time to achieve endogenous throm-
bolysis of the thrombus created during the first phase of
the test (Fig 2). The principle of the GTT has previously
been described in detail [3, 4]. Briefly, the GTT test tube
has a conical part in which two ceramic ball bearings are
located. Because of the four flat segments formed on the
inner surface of the tube, four narrow gaps exist by the
ball bearings. Blood was drawn from the antecubital vein
via a 21G infusion set into three 5 ml plastic syringes, tak-
ing care to avoid prolonged tourniquet time. When whole
blood (4 ml) is added to the GTT disposable tube, it flows
through the narrow gaps by the ball bearings and the
droplets are collected in a reservoir. Passing through the
gaps by the upper (larger) ball bearing, platelets are ex-
posed to high shear stress and activated. In the space be-
tween the two balls, platelet aggregates are formed and
thrombin is generated from the activated platelets. As the
fibrin-stabilized thrombi reach and gradually occlude the
gaps by the lower ball bearing, blood flow is reduced and
then arrested. The instrument measures the time between
2 consecutive blood drops. This time interval increases
gradually as flow slows down. The end point of the meas-
urement is displayed (occlusion time [OT], in seconds).
Subsequent to OT, this system can measure endogenous
thrombolytic activity by detecting the time taken until re-
start of blood flow (lysis time [LT], in seconds).
Follow up and clinical endpoints
Patients were followed up for approximately 18 months
for the co-primary endpoints of ischemic events (stroke,
non-fatal acute myocardial infarction or cardiovascular
death) or major bleeding (classified as type 3–5 according
to the Bleeding Academic Research Consortium, BARC
definition) [5].
Fig. 1 Study protocol: one day before changing the therapy from warfarin to dabigatran and one month after initiating dabigatran therapy,
thrombotic status was assessed using the global thrombosis test (GTT), prothrombin time-international normalized ratio (PT-INR), and activated
partial thrombin time (APTT) in patients with non-valvular atrial fibrillation. OT, occlusion time
Otsui et al. Thrombosis Journal  (2015) 13:39 Page 2 of 5
Statistical analysis
Continuous variables are expressed as medians and inter-
quartile ranges. Differences between the two groups were
analyzed by the Wilcoxon matched paired test. The cor-
relation between variables was evaluated by Spearman’s
rank correlation coefficient. Statistical analyses were
performed using IBM SPSS Statistics Version 22. A
p-value of <0.05 was considered statistically significant.
Result and discussion
The non-inferiority of dabigatran compared to warfarin
was confirmed by several clinical trials [1] and dabiga-
tran was approved and launched in Japan in late March
2011. However, a considerable number of patients have
had severe bleeding, especially among subjects with renal
dysfunction [6, 7]. Therefore, there is a compelling need
for a monitoring system for dabigatran. The present inves-
tigation was undertaken to examine whether the GTT sys-
tem could be the monitoring system for dabigatran.
The OT and LT values assessed by the GTT in normal
volunteers without anticoagulants were 524.9 ± 17.0 sec
and 1409.8 ± 100.7 sec, respectively. Activated partial
thromboplastin time (APTT) and the OT values of
NVAF patients under warfarin therapy ranged from 24.1
to 47.0 (mean 35.5 ± 0.7) sec and from 187.9 to 900
(mean 581.7 ± 26.3) sec, respectively. Switching anti-
coagulation from warfarin to dabigatran resulted in
Fig. 2 Global thrombosis test (GTT), which is used to measure platelet reactivity, coagulation (thrombin generation), and spontaneous (endogenous)
thrombolytic activity
Table 1 A clinical profile of subjects
Age 76.5 ± 1.4
Male sex, N (%) 27 (62.8 %)
Follow up period (months) 14.7 ± 1.6
CHA2DS2 –VASc score, N (%)
0 or 1 point 3 (7.0 %)
2 points 3 (7.0 %)
3 points 11 (25.5 %)
≥ 4 points 26 (60.5 %)
HAS-BLED Score, N (%)
0 point 4 (9.3 %)
1 point 13 (30.2 %)
2 points 12 (27.9 %)
≥ 3 points 14 (32.6 %)
Hypertension, N (%) 28 (65.1 %)
Diabetes, N (%) 12 (27.9 %)
Dyslipidemia, N (%) 31 (69.8 %)
Concomitantly taking anti-platelets
Aspirin, N (%) 21 (48.8 %)
Clopidogrel, N (%) 2 (4.7 %)
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significant prolongation of the APTT values from 35.5 ± 0.7
to 44.8 ± 1.8 sec (Fig 3a). There was also prolongation of
the OT values from 581.7 ± 26.3 to 784.5 ± 19.3 sec
(Fig 3b). In contrast, there was no significant change in LT
in response to the change in anticoagulation (Fig 3c).
Therefore, dabigatran appears to exert no additional effect
on endogenous thrombolytic activity, over and above that
of anticoagulation.
The OT value measured by the GTT system reflects
not only platelet reactivity to pathologically relevant high
shear stress but also thrombin generation [4]. In other
words, the GTT can simultaneously assess both platelet
reactivity and the pro-coagulant state. Warfarin inhibits
the pro-coagulant state by the suppression of vitamin
K-dependent coagulation factors. Since thrombin is a po-
tent activator of platelets, dabigatran, a potent thrombin
inhibitor, could affect the platelet activity. Indeed, Eisert
WG et al. reported that dabigatran did not inhibit platelet
aggregation when induced by arachidonic acid, collagen,
or ADP in human platelet rich plasma. However, platelet
aggregation activated by thrombin was inhibited by dabi-
gatran [8]. This property could explain our findings that
switching anticoagulation from warfarin to dabigatran re-
sulted in the prolongation of the OT.
APTT as well as OT values as assessed by the GTT in
NVAF patients were significantly increased by switching
anticoagulation from warfarin to dabigatran. These find-
ings suggest the possibility that GTT could be the moni-
toring system for NOAC including dabigatran. Recently,
Suzuki et al. demonstrated a wide distribution of APTT
values in Japanese NVAF patients receiving dabigatran
therapy, and they proposed that the monitoring by APTT
might aid in the screening of patients at increased bleed-
ing risk with dabigatran [9]. We examined the correlation
between the OT value and APTT or PT-INR. Spearman’s
rank correlation coefficient and p- values between OT
value and APTT were 0.245 and 0.114, respectively.
Spearman’s rank correlation coefficient and p- values be-
tween OT value and PT-INR were 0.178 and 0.254, re-
spectively. Thus, there was no significant correlation
between OT and APTT or PT-INR. Therefore, the OT
value evaluated by the GTT is independent of APTT or
PT-INR.
At elevated shear stress such as that which occurs in a
stenosed coronary artery, platelet thrombus formation
depends entirely on von Willebrand factor (vWF) bind-
ing to platelet glycoproteins Ib/IX/V and IIb/IIIa. Shear-
induced platelet activation and aggregation is initiated
by the plasma vWF interacting with the platelet GPIb/
IX/V complex and platelet crosslinking through integrin-
aIIbβ3. In addition to its role in platelet activation and
aggregation, vWF has an important role in physiological
hemostasis, in the formation of platelet plugs at sites of
endothelial damage. VWF binds to the exposed sub-
endothelium and forms a bridge between this surface
and to the platelets, where it binds to glycoprotein com-
plexes Ib/IX/V and IIb/IIIa, which act as vWF receptors.
Inherited deficiencies or dysfunctions of vWF cause a
bleeding disorders and vWF level correlates inversely
with bleeding risk [10]. Earlier published research evalu-
ating the mechanism of the thrombotic occlusion in the
GTT has revealed the fundamental role of vWF in deter-
mining the OT value. Antagonism of vWF with aurin
tricarboxylic acid (ATA) significantly inhibited OT in the
GTT [11]. Furthermore, platelet-rich thrombus for-
mation in the GTT was dose-dependently inhibited by
monoclonal antibody against platelet glycoprotein (GP) Ib.
The OT value was inversely correlated with vWF ristocetin
Fig. 3 In patients with non-valvular atrial fibrillation, changes in (a) activated partial thrombin time (APTT), (b) occlusion time (OT), and (c) lysis
time (LT) following a change from warfarin therapy (left) to dabigatran (right) therapy. The use of dabigatran significantly prolonged APTT as well
as OT, compared with warfarin, while there was no change in LT
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cofactor activity and vWF antigen. This report is the first
to clearly demonstrate the role of vWF in the formation of
occlusive thrombi in the Gorog Thrombosis Test [12].
Thus, the OT value in the GTT system is directly deter-
mined by vWF. Although our present study was not
powered to assess the predictive value of prolonged OT on
the risk/propensity for bleeding, intuitively, since vWF is a
sensitive marker of bleeding risk, it seems reasonable to
suppose that extreme prolongation of OT will be related
to increased bleeding risk. In the present investigation, the
number of subjects with OT > 900 sec on warfarin therapy
was one among 43 NVAF patients, whereas with dabigatran
therapy there were 12 patients with OT > 900 sec. There
were no ischemic events and no major bleeds observed
amongst the patients during the follow up period of (14.7 ±
1.6 months). Further assessment of this in larger popula-
tions followed up for a longer period is necessary to better
evaluate the usefulness of OT, as assessed by the GTT as a
monitoring system to assess bleeding risk with NOAC.
Antithrombotic therapy for the prevention of cardiovas-
cular disease and ischemic stroke is inevitably associated
with bleeding risk; therefore, the most crucial thing is to
reconcile the two conflicting aspects, that is, the anti-
thrombotic effects and the bleeding risk. To this end, it
would be highly desirable to establish clinical tools for es-
timation of coagulant and thrombotic status. The inci-
dence of NVAF increases with age; therefore, concomitant
atherosclerosis-based cardiovascular diseases such as an-
gina pectoris and myocardial infarction also occur more
frequently. In such cases, the combination of anticoagula-
tion and antiplatelet therapy is necessary, but the bleeding
risk is inevitably increased with combination therapy. A
comprehensive assessment is important for assessment of
the thrombotic risk, as well as bleeding, in patients treated
with antiplatelet therapy and anticoagulation. Since the
GTT can simultaneously assess both platelet reactivity and
the pro-coagulant state, this system seems to have signifi-
cant potential for the assessment of ischemic risk in vari-
ous cardiovascular disease states. Furthermore, the GTT
system has several advantages over previous methods. The
GTT does not require anti-coagulants for the measure-
ment, and the results are unaffected by the procedure of
sample preparations. Right now a large scale of clinical
trial using the GTT system is under progression.
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